Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on October 8, 2020, reporting events occurring on October 7, 2020. The Company is an emerging growth company focused on medical device development, specifically its lead products VenoValve and CoreoGraft.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5,100,000 from a registered direct offering and concurrent private placement.
- Net Proceeds: Approximately $4,600,000 after deducting placement agent fees and expenses (before estimated offering expenses).
- Securities Issued: 9,532,709 shares of Common Stock and warrants to purchase an equal number of shares.
- Offering Price: $0.535 per share and warrant unit.
- Warrant Terms: Exercise price of $0.41 per share; exercisable immediately; expire seven years from issuance.
- Placement Agent Fees: 8.0% cash fee, 1.5% management fee, and warrants equal to 6.0% of shares sold.
Material Changes
The filing reports the entry into a Material Definitive Agreement for a capital raise. This represents a significant change in the Company's capital structure and liquidity position, increasing cash reserves for product development. No prior period financial data is provided in this specific filing for comparison.
Outlook, Management Commentary, and Risks
Use of Proceeds: The Company intends to use net proceeds for the continued development of VenoValve and CoreoGraft, as well as general corporate purposes and working capital.
Closing Date: Expected on or about October 9, 2020, subject to customary conditions.
Risks/Contingencies: The transaction is subject to closing conditions. The Warrants are being sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Investor Verification Checklist
- Verify the actual closing date and final gross/net proceeds once the transaction completes.
- Confirm the dilution impact of the 9,532,709 new shares and associated warrants on existing shareholders.
- Review the filed Prospectus Supplement (Form S-3 takedown) for detailed risk factors and use of proceeds.
- Monitor the Company's cash burn rate relative to the $4.6 million net proceeds to assess runway for product development.